This clinical situation with SS is consistent with dominant TNFR2 antagonistic antibodies having the enhanced ability to target newly produced surface TNFR2 if the cancer cells are rapidly proliferating. This evidence concerns the gene TNFRSF1B and synovial sarcoma.